Robert Dreicer, MD from the Taussig Cancer Institute Remarks on Disparities in the Healthcare System
July 17th, 2026Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With CancerLaure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.Read more